ID Source | ID |
---|---|
PubMed CID | 656634 |
CHEMBL ID | 1788290 |
MeSH ID | M0582610 |
Synonym |
---|
l-1-(3,4,5-trimethylbenzyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline |
6,7-isoquinolinediol, 1,2,3,4-tetrahydro-1-((3,4,5-trimethoxyphenyl)methyl)-, hydrochloride, (s)- |
trimetoquinol (van) |
l-1-(3,4,5-trimethoxybenzyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline hydrochloride |
tretoquinol l-form hydrochloride |
1-(3,4,5-trimethoxybenzyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline hydrochloride, l- |
einecs 242-423-5 |
triquinol |
l-trimetoquinol |
nsc 288748 |
6,7-isoquinolinediol, 1,2,3,4-tetrahydro-1-(3,4,5-trimethoxybenzyl)-, hydrochloride, (-)- |
trimethoquinol (van) |
ccris 1913 |
trikvinol (triquinol) hydrochloride |
trimethoquinol |
18559-59-6 |
trimetoquinol-hydrochloride |
aql 208 |
D01978 |
inolin (tn) |
trimetoquinol hydrochloride |
CHEMBL1788290 |
NCGC00182977-01 |
unii-298sp836n4 |
298sp836n4 , |
cas-18559-59-6 |
tox21_113220 |
dtxcid8028682 |
dtxsid1048756 , |
tretoquinol l-form hydrochloride [mi] |
(-)-1,2,3,4-tetrahydro-1-(3,4,5-trimethoxybenzyl)isoquinoline-6,7-diol hydrochloride |
tretoquinol hydrochloride anhydrous |
anhydrous tretoquinol hydrochloride |
6,7-isoquinolinediol, 1,2,3,4-tetrahydro-1-((3,4,5-trimethoxyphenyl)methyl)-, hydrochloride (1:1), (1s)- |
anhydrous tretoquinol hydrochloride [mart.] |
(1s)-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline-6,7-diol;hydrochloride |
(-)-trimetoquinol; aql 208; bentomex; inolin; nsc 288748 |
Q27254403 |
s-(-)-tretoquinol hydrochloride |
Excerpt | Reference | Relevance |
---|---|---|
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
AR protein | Homo sapiens (human) | Potency | 26.8325 | 0.0002 | 21.2231 | 8,912.5098 | AID743036 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 10.6822 | 0.0002 | 29.3054 | 16,493.5996 | AID743069 |
aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 33.4915 | 0.0007 | 23.0674 | 1,258.9301 | AID743085 |
Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 5.6234 | 0.0096 | 10.5250 | 35.4813 | AID1479145 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
virion membrane | Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
AID1146267 | Agonist activity at beta 2 adrenergic receptor in Sprague-Dawley rat adipocytes assessed as lipolysis after 1 hr | 1977 | Journal of medicinal chemistry, Nov, Volume: 20, Issue:11 | Synthesis of 1-substituted analogues of trimetoquinol possessing differential and selective beta-adrenergic properties. |
AID41015 | Compound was evaluated for beta-2 adrenergic receptor activity on carbachol-contracted guinea pig tracheal strips | 1986 | Journal of medicinal chemistry, Sep, Volume: 29, Issue:9 | Syntheses and beta-adrenergic agonist and antiaggregatory properties of N-substituted trimetoquinol analogues. |
AID92815 | Compound was evaluated for the inhibition of U-46,619-induced human platelet aggregation (Antiaggregatory activity) | 1986 | Journal of medicinal chemistry, Sep, Volume: 29, Issue:9 | Syntheses and beta-adrenergic agonist and antiaggregatory properties of N-substituted trimetoquinol analogues. |
AID92819 | Compound was evaluated for the secretion of [14C]- Serotonin (Antisecretory activity) | 1986 | Journal of medicinal chemistry, Sep, Volume: 29, Issue:9 | Syntheses and beta-adrenergic agonist and antiaggregatory properties of N-substituted trimetoquinol analogues. |
AID1146265 | Agonist activity at beta 2 adrenergic receptor in guinea pig trachea assessed as tracheal relaxation | 1977 | Journal of medicinal chemistry, Nov, Volume: 20, Issue:11 | Synthesis of 1-substituted analogues of trimetoquinol possessing differential and selective beta-adrenergic properties. |
AID39963 | Compound was evaluated for beta-1 adrenergic receptor activity in spontaneously beating guinea pig right atria. | 1986 | Journal of medicinal chemistry, Sep, Volume: 29, Issue:9 | Syntheses and beta-adrenergic agonist and antiaggregatory properties of N-substituted trimetoquinol analogues. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (40.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 2 (40.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |